On October 17th, the prospectus issued by the Hong Kong Stock Exchange showed that Nuocheng Jianhua, co-founded by Shi Yigong, an academician of China Academy of Sciences and president of West Lake University, and Dr. Cui Jisong, had submitted an application for listing in Hong Kong.
according to this prospectus, the final valuation was 88 million USD, and the accumulated financing exceeded 28 million USD. Since 216, the company has successively obtained financing, of which the maximum single amount exceeds 16 million US dollars, which was completed in June this year.
Screenshot of the prospectus
According to the shareholder structure, Dr. Cui Jisong holds 11.45%, and Professor Shi Yigong and Dr. Zhao Renbin hold 15.43%.
Star Scientists Lead Listed Companies
Shi Yigong is a world-renowned structural biologist.
combing his resume, it is found that in 28, after successively serving as assistant professor, associate professor, tenured professor and Warner-Lambert/Park-Davis chair professor in the Department of Molecular Biology of Princeton University in the United States, he resolutely resigned and returned to China as the dean of the School of Life Sciences of Tsinghua University, becoming a star scientist in the academic circle.
In p>213, he was elected as an academician of Chinese Academy of Sciences; In 214, he was attached to the Beijing Municipal Health Planning Commission as the deputy director; In 215, he became Vice President of Tsinghua University.
In p>218, Shi Yigong resigned as the vice president of Tsinghua University, founded West Lake University and served as the first president.
Shi Yigong holds several posts, and his academic strength is still impressive. According to Google's personal academic archives in Shi Yigong, so far, Shi Yigong has published 229 papers and been cited 43,883 times.
According to official website of Nuocheng Jianhua Company, Shi Yigong is the chairman of the scientific advisory committee of the company.
combing Shi Yigong's business experience, including Nuocheng Jianhua, Shi Yigong has participated in five companies.
what does this company do? Three new drugs enter clinical trials!
Shi Yigong co-founded this company. What does he want to do?
according to official website, the company mainly treats autoimmune diseases and tumor diseases, especially systemic lupus erythematosus, rheumatoid arthritis, chronic lymphocytic leukemia, liver cancer, gastric cancer and cholangiocarcinoma.
At present, the company has:
a candidate drug that can be directly registered in the second phase of clinical trials;
two drug candidates in phase I/II trial;
six candidate drugs in the preparation stage of IND.
some products are mainly under research:
obutinib is the core candidate product of the company.
On October 5th, the company announced the data of two clinical trials of ICP-22 in the treatment of lymphoma and leukemia at the 61st annual meeting of the American Hematology Association, and studied its efficacy as monotherapy and combined therapy.
new drugs related to tumor treatment, such as ICP-15 and ICP-192, are being tackled.
In fact, Shi Yigong has also set foot in medicine and business.
around p>2, the research group led by him analyzed the structure of an apoptosis inhibitor. This factor will prevent cells from apoptosis normally, which will cause cancer.
during the analysis, they found that cancer cells can return to normal apoptosis as long as a small peptide of a protein is embedded into the carcinogen.
this discovery has aroused great interest of pharmaceutical companies, and related scientific research patents have been transformed into new drugs for treating cancer and entered clinical trials.
Chinese biologists run companies. Who else?
According to incomplete statistics, many biologists have established companies all over the world, they are:
Wang Xiaodong
Foreign academician of China Academy of Sciences, academician of American National Academy of Sciences, and director of Beijing Institute of Life Sciences
His research focuses on biochemical pathways and biochemical processes of apoptosis.
In p>211, Wang Xiaodong founded Baekje Shenzhou, the first China new drug research and development company listed in the United States, with the main research and development objectives of new molecular targeted drugs and tumor immune drugs.
Chen Lieping
Director of Institute of Immunotherapy, Fujian Medical University, UTC Chair of Cancer Research at Yale University, and Director of Immunology Department of Yale Cancer Center
Engaged in relevant research on immunological mechanism, tumor immunotherapy and immune disease treatment. It is the first method to block PD-1/PD-L1 pathway with antibody to treat cancer.
NextCure Biomedical Company, founded by Exhibition Ping, focuses on discovering and developing the next generation of immune drugs to treat cancer and other diseases. In May this year, the company was listed on NASDAQ.
Zhang Feng
Academician of American College of Humanities and Sciences, tenured professor of Science College of Massachusetts Institute of Technology
His most famous work is the development and application of gene modification technology CRISPR-Cas9, and he took the lead in obtaining American patent.
Because of his breakthrough work in gene editing technology CRISPR-Cas9, Zhang Feng founded EditasMedicine with venture capital and successfully went public.
in p>217, Feng Zhang and others set up a new biotechnology company Arbor Biotechnology.
Zhang Yi
Professor of Harvard Medical School. One of the top ten scientists who have been selected as influential papers in the field of molecular biology and genetics in Science Watch < P > has discovered a variety of enzymes related to epigenetic regulation and two new DNA bases. The latter has changed the original view that there are only six DNA bases, which is of great significance for the study of stem cells and cancer.
Epizyme, a biotechnology company he founded with Nobel Prize winner Horvitz***, was also listed on Nasdaq in 213.
Cheng Jing
Academician of China Academy of Engineering, Professor Tsinghua University, Director of Beijing National Engineering Research Center for Biochips
Mainly engaged in the research and development of DNA chips, protein chips, cell chips and microchip microfabrication laboratories, as well as the application research in health management, disease diagnosis, food safety testing and drug development, as well as the research related to big health management relying on Internet big data and artificial intelligence.
In p>2, he founded Boao Bio-Group with biochip as the core technology platform, and is now planning to go public.
It can be seen that with the continuous development of the frontier of biotechnology, it is expected that biologists will directly push the frontier scientific research results to the market, which will accelerate science to bring benefits to human health.
what are your expectations for Chinese biologists to start their own businesses? I'll see you in the message area!
Resources:
Cooperation matters:
Submission matters:
Heart of the King 2 Click for a demo.